Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials.

ABSTRACT:

Purpose

Pancreatic ductal adenocarcinoma (PDAC) remains a common and difficult cancer to treat. Surgical resection and chemotherapy are standard of care and clinical outcomes remain poor. Oncolytic adenoviruses are a unique approach to the treatment of this challenging cancer, aiming to overcome the features of this disease that pose the key obstacles to standard therapies. This paper provides a detailed review of the clinical trials of conditionally-replicative adenoviruses in pancreatic cancer to date, with a brief summary of the past preclinical literature and future prospects of this therapy.

Methods

MEDLINE, Embase, and clinicaltrials.gov were searched from inception to December 23rd 2022 for clinical trials of conditionally-replicative adenoviruses used in patients wit

SUBMITTER: Taylor IP 

PROVIDER: S-EPMC10374677 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature